No Prescription |
 |
 | ||
|
Parit AcipHex |
|
| ||
No Prescription » Prescription Drugs 13 » Parit AcipHex Rabeprazole is used to treat conditions where the stomach produces too much acid including ulcers gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. Rabeprazole is used in combination with other medications to eliminate H. pylori a bacterium that causes ulcers. Rabeprazole is in a class of medications called proton-pump inhibitors. It works by decreasing the amount of acid made in the stomach. Buy Parit AcipHex and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About Parit AcipHex: Product Type: Prescription Drugs 13 Parit (AcipHex Generic Rabeprazole) Parit (AcipHex Generic Rabeprazole) AcipHex Generic Rabeprazole 20mg AcipHex Generic Rabeprazole Parit
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
